Incidence of Postoperative Residual Neuromuscular Blockade in Portugal
NCT ID: NCT03417804
Last Updated: 2021-07-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
366 participants
OBSERVATIONAL
2018-06-18
2019-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Subjects aged at least 18 years old (n=360) admitted for different types of elective surgical procedures requiring general anesthesia with neuromuscular blocking agents will be included.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Incidence of Incomplete Postoperative Neuromuscular Recovery From Anesthesia (P07535)(Completed)
NCT01181349
Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?
NCT02484651
Comparison of Three Methods of Anesthesia to Achieve a Nerve Block Anesthesia.
NCT05345665
Algorithm of Muscle Function Tests to Detect Residual Neuromuscular Blockade.
NCT03219138
Evaluation of Residual Neuromuscular Blockade and of Late Recurarization in the Post Anesthesia Care Unit in Patients Undergoing Videolaparoscopic Cholecystectomy
NCT03831815
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will have two periods:
* Period 1 - Evaluation at PACU arrival.
* Period 2 - Collection of hospital patient discharge data.
A total of 360 patients will be included from approximately 10 centers in Portugal, where the PACU is adjacent to the Operating Room (OR). Each center should recruit between 30 and 40 patients.
Each subject is considered to be enrolled in the study when the subject has provided written informed consent.
Enrollment will be stopped when approximately 360 patients are recruited.
A subject is considered to have completed the trial after all of the protocol specified activities are completed. A subject is considered to have discontinued after he/she has withdrawn consent or has been discontinued.
Overall, study start is when the first site is initiated and study ends at database lock.
During the routine preoperative anesthesia visit the patient will be asked to participate in the study. A description of the study will be provided to the patient by the investigator or qualified designee and any questions will be properly answered. If the patient agrees to participate in the study an informed consent form (ICF) will be signed.
Consent must be documented by the subject's dated signature or by the subject's legally acceptable representative's dated signature on a consent form along with the dated signature of the person conducting the consent discussion. A copy of the signed and dated consent form should be given to the subject before participation in the study.
The initial informed consent form, any subsequent revised written informed consent form and any written information provided to the subject must receive the IRB/ERC's (Institutional Review Board) ) approval/favorable opinion in advance of use. The subject or his/her legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the subject's willingness to continue participation in the study.
All consented subjects will be given a unique patient number that will be used to identify the subject for all procedures. Each subject will be assigned only one patient number.
Immediately after patient arrival in the PACU and as soon as clinically adequate (basic monitoring and oxygen therapy in place) the anesthesiologist assigned to the PACU (who was not involved in the anesthetic procedure) will collect demographic data (gender, age, weight, height), vital signs (heart rate, blood pressure, oxygen saturation and temperature). Neuromuscular blockade (TOF Ratio) will be measured. Clinical history, co-morbidities, surgical diagnosis, ASA (American Society of Anesthesiology) classification and perioperative medication data (dosage and last administration time) will be collected as well.
As this is an observational study, intra-operative monitoring of neuromuscular blockade will not be mandatory by protocol and will be left at the discretion of the anesthesiologist as according to the clinical practice. Only information about whether this evaluation was performed or not, and if yes if it was used quantitative or qualitative methods, will be collected in the CRF (case report form) .
Neuromuscular blockade evaluation Neuromuscular blockade will be evaluated using a quantitative method. Three consecutive TOF stimulations will be applied. In case these 3 measures differ more than 20%, another sequence of 3 consecutive TOF measurements will be considered. If after the 2nd sequence the 3 consecutive TOF measurements still differ more than 20% between the maximum and the minimum the patient will be excluded.
This study will reflect real life clinical practice. The anesthetic technique in terms of drugs and type of monitoring used will be of entire responsibility of the anesthesiologist.
All study activities will be consistent with EU (European Union) directive 2001/20/EC section for non- interventional studies :
* NMBAs (neuromuscular blocking agents) and reversal agents (as well as all drugs which will be used during the anesthesia) administration will be done in accordance with routine anesthesiology practice and labeling of these medicine products;
* No further interventional means, methods or procedures, are scheduled for subjects, which would otherwise not be applied;
* Furthermore, there will be no additional visits to the hospital or a mandatory visit schedule, deviating from daily clinical practice.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent signed;
* Admission for elective surgery;
* Administration of non-depolarizing NMBAs during surgery
Exclusion Criteria
* Reoperation on the same hospital admission;
* More than 10 minutes elapsed between extubation and neuromuscular block monitoring at PACU
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centro Hospitalar do Porto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Simao Esteves
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Simao Esteves, MD
Role: PRINCIPAL_INVESTIGATOR
Centro Hospitalar do Porto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Prof. Fernando Fonseca, EPE
Amadora, , Portugal
Centro Hospitalar Baixo Vouga
Aveiro, , Portugal
Centro Hospitalar Universitário de Coimbra
Coimbra, , Portugal
Centro Hospitalar Lisboa Norte
Lisbon, , Portugal
Hospital Pedro Hispano
Matosinhos Municipality, , Portugal
Centro Hospitalar Tamega Sousa
Penafiel, , Portugal
Centro Hospitalar do Porto
Porto, , Portugal
Centro Hospitalar S. João
Porto, , Portugal
Centro Hospitalar Vila Nova Gaia/Espinho
Vila Nova de Gaia, , Portugal
Centro Hospitalar Tondela Viseu
Viseu, , Portugal
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017.156(133-DEFI/125-CES)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.